Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function | Zendy

Mark D. Pescovitz | Zendy; Carla J. Greenbaum | Zendy; Heidi KrauseSteinrauf | Zendy; Dorothy J. Becker | Zendy; Stephen E. Gitelman | Zendy; Robin Goland | Zendy; Peter A. Gottlieb | Zendy; Jennifer B. Marks | Zendy; Paula McGee | Zendy; Antoinette Moran | Zendy; Philip Raskin | Zendy; Henry Rodriguez | Zendy; Desmond Schatz | Zendy; Diane K. Wherrett | Zendy; Darrell M. Wilson | Zendy; John M. Lachin | Zendy; Jay S. Skyler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Author(s) -

Mark D. Pescovitz,

Carla J. Greenbaum,

Heidi KrauseSteinrauf,

Dorothy J. Becker,

Stephen E. Gitelman,

Robin Goland,

Peter A. Gottlieb,

Jennifer B. Marks,

Paula McGee,

Antoinette Moran,

Philip Raskin,

Henry Rodriguez,

Desmond Schatz,

Diane K. Wherrett,

Darrell M. Wilson,

John M. Lachin,

Jay S. Skyler

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0904452

Subject(s) - medicine , rituximab , glycated hemoglobin , placebo , gastroenterology , lymphocyte , diabetes mellitus , immunology , cd20 , type 1 diabetes , type 2 diabetes , endocrinology , lymphoma , pathology , alternative medicine

The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research